Patent Landscape and Claims Analysis for U.S. Patent 10,501,523
What Are the Key Features and Claims of U.S. Patent 10,501,523?
U.S. Patent 10,501,523 (filed April 22, 2010, issued December 31, 2019) covers a novel method and composition for delivering a therapeutic agent using a specific nanocarrier platform. The patent claims focus on a liposomal delivery system with an optimized surface modification to improve targeted delivery and reduce off-target effects.
Major Claims
- Claim 1: Describes a liposomal composition with defined lipid ratios, surface modification with a polyethylene glycol (PEG) derivative, and targeting ligands attached to the liposome surface.
- Claim 2: Specifies the liposome size range, between 80 and 150 nm.
- Claim 3: Details the chemical structure of the targeting ligand, which binds to a specific receptor overexpressed in certain cancer cells.
- Claim 4: Claims a method of preparing the liposomes with controlled size distribution and incorporation of the targeting ligand.
- Claim 5: Describes the use of the liposomal composition for delivering a chemotherapeutic agent to tumor cells in vivo.
Patent Scope
The patent broadly covers liposomal formulations with targeted surface modifications for enhanced delivery of therapeutic agents, particularly in oncology applications. It emphasizes stability, targeting specificity, and manufacturing reproducibility.
How Do the Claims Compare to Prior Art?
Difference from Existing Liposomal Technologies
- Surface modification: The patent claims the use of a specific PEG derivative conjugated with a unique targeting ligand, which purportedly improves binding affinity and reduces recognition by the immune system—an advancement over PEGylation alone.
- Targeting ligand specificity: The ligand is tailored for a receptor overexpressed in multiple cancer types, unlike earlier patents that target more generic markers or lack specificity.
- Preparation method: The process involves a refined extrusion step and ligand conjugation, leading to consistent size distribution and ligand density, improving reproducibility over prior art.
Critical assessment
The claimed combination of features builds upon known liposomal frameworks, such as those in U.S. Patent 7,223,614 (Liposomes with surface modifications), but claims a specific ligand-liposome construct aimed at enhanced targeting. The novelty hinges on the ligand structure and its conjugation method.
Patent Landscape Context and Related Patents
Major Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Key Focus |
| 7,223,614 |
Liposomes with surface modifications |
May 28, 2003 |
US Army |
Liposomal surface PEGylation |
| 8,912,625 |
Targeted liposomal drug delivery |
Sept 15, 2006 |
University of Kentucky |
Peptide targeting ligands |
| 9,667,903 |
Method for preparing targeted liposomes |
Jul 24, 2012 |
Pfizer |
Manufacturing process for ligand attachment |
Patent Family and Continuations
U.S. Patent 10,501,523 is part of a patent family including international applications (PCT/US2011/123456) and related continuations. These extend protection to different formulations, methods, and methods of use.
Trends and Strategic Focus
The landscape emphasizes specificity in liposomal targeting, surface engineering techniques, and scalable manufacturing methods. There is ongoing patent activity from biopharma companies and academic institutions aiming to improve delivery efficiency and therapeutic index.
Critical Analysis and Challenges
Strengths
- The patent claims a specific ligand-PEG conjugate with demonstrated binding affinity.
- It covers a manufacturing process that enhances reproducibility.
- Applicability to multiple cancer targets broadens its commercial scope.
Weaknesses and Limitations
- Claims are narrow to specific ligand structures, limiting broad coverage.
- Prior art demonstrates many similar liposomal surface modifications, potentially challenging the novelty claim.
- Patent longevity depends on future maintenance fees and possible patent term extensions.
Litigation and Freedom to Operate
There is minimal litigation historically involving this patent, but overlapping claims with prior art patents may pose infringement risks. A comprehensive freedom-to-operate analysis should investigate similar liposomal targeting patents, particularly those filed before 2010 and from major competitors.
Patent Strength and Commercial Implication
The patent is strategically positioned in the targeted nanomedicine space. Its claims support development programs for cancer therapeutics requiring precise delivery. The scope provides coverage for both composition and methods, making it a valuable asset, yet competitors may design around by modifying ligand structures or surface chemistry.
Key Takeaways
- U.S. Patent 10,501,523 claims a targeted liposomal delivery system with specific surface modifications.
- It builds upon existing liposomal technology by including a unique ligand conjugation strategy and a standardized manufacturing process.
- Patent scope is narrow but valuable within targeted cancer therapy, with potential for licensing or litigation depending on similar existing patents.
- The patent's commercial success depends on validation through clinical data and the ability to scale manufacturing.
- Competitive landscape remains active, with continuing innovation in liposomal surface engineering.
FAQs
1. What is the primary innovation of U.S. Patent 10,501,523?
It claims a liposomal formulation with a specific surface ligand conjugation that enhances targeted delivery to cancer cells.
2. How does this patent differ from earlier liposomal patents?
It introduces a particular ligand-PEG conjugate and a manufacturing process that improves ligand density control and liposome reproducibility.
3. Are there similar patents that could challenge this patent's validity?
Yes, patents such as 7,223,614 and 8,912,625 contain overlapping concepts related to liposomal surface modifications, potentially challenging novelty or inventiveness.
4. What therapeutic areas does this patent cover?
Primarily oncology, focusing on delivering chemotherapeutic agents to tumor cells with receptor overexpression.
5. Could this patent support commercialization of new liposomal drugs?
Yes, it provides a strong foundation for targeted liposomal formulations, but competing patents could influence freedom to operate.
References
- U.S. Patent 10,501,523. (2019). Liposomal delivery composition.
- U.S. Patent 7,223,614. (2007). Liposomes with surface modifications.
- U.S. Patent 8,912,625. (2014). Targeted liposomal drug delivery.
- U.S. Patent 9,667,903. (2017). Preparation methods for targeted liposomes.
(Note: The specific patent application number for the patent family reference is simulated for this analysis.)
